种族不是不利前列腺癌的预后因素:一项ndb分析

J. Kodiyan, M. Ashamalla, A. Guirguis, H. Ashamalla
{"title":"种族不是不利前列腺癌的预后因素:一项ndb分析","authors":"J. Kodiyan, M. Ashamalla, A. Guirguis, H. Ashamalla","doi":"10.1097/IJ9.0000000000000086","DOIUrl":null,"url":null,"abstract":"Supplemental Digital Content is available in the text. Introduction: It is commonly held that race serves as a significant prognosticator in prostate cancer. We sought to analyze whether race impacted overall survival (OS) of men receiving standard of care treatment. Materials and Methods: All data was obtained from the NCDB (National Cancer Database) and initially contained 1,294,126 cases of prostate cancer diagnosed between 2004 and 2013. Patients were excluded if they had metastatic or nodal disease, received chemotherapy, or had noninvasive disease. Patients were grouped into 2 cohorts as per NCCN (National Comprehensive Cancer Network) criteria: favorable risk and unfavorable risk. All patients received risk-appropriate radiation therapy or surgery, and were subsequently analyzed. Black and white men were also matched 1:1 within each risk cohort using propensity scores, and multivariate analysis was conducted on these matched cohorts. Results: The final cohort 77,448 patients. Median follow-up 58.7 months (range, 48–143.5). In the favorable risk cohort, white men had superior OS compared with black men, 77.63% versus 80.57% at 10 years (hazard ratio, 0.644; 95% confidence interval, 0.536–0.773; P<0.001). In the unfavorable cohort, race was not a significant prognostic factor for OS on unmatched analysis; 10-year survival 73.6% and 71.3% (hazard ratio, 0.941; 95% confidence interval, 0.848–1.044; P=0.249), and significant interaction existed with age. Results were unchanged in propensity score matched cohorts. Conclusion: The prognostic value of race-related biological differences of prostate cancer may hold less value in higher risk disease than is commonly believed.","PeriodicalId":42930,"journal":{"name":"International Journal of Surgery-Oncology","volume":"37 1","pages":"e86 - e86"},"PeriodicalIF":0.3000,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Race is not prognostic in unfavorable prostate cancer: an NCDB analysis\",\"authors\":\"J. Kodiyan, M. Ashamalla, A. Guirguis, H. Ashamalla\",\"doi\":\"10.1097/IJ9.0000000000000086\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Supplemental Digital Content is available in the text. Introduction: It is commonly held that race serves as a significant prognosticator in prostate cancer. We sought to analyze whether race impacted overall survival (OS) of men receiving standard of care treatment. Materials and Methods: All data was obtained from the NCDB (National Cancer Database) and initially contained 1,294,126 cases of prostate cancer diagnosed between 2004 and 2013. Patients were excluded if they had metastatic or nodal disease, received chemotherapy, or had noninvasive disease. Patients were grouped into 2 cohorts as per NCCN (National Comprehensive Cancer Network) criteria: favorable risk and unfavorable risk. All patients received risk-appropriate radiation therapy or surgery, and were subsequently analyzed. Black and white men were also matched 1:1 within each risk cohort using propensity scores, and multivariate analysis was conducted on these matched cohorts. Results: The final cohort 77,448 patients. Median follow-up 58.7 months (range, 48–143.5). In the favorable risk cohort, white men had superior OS compared with black men, 77.63% versus 80.57% at 10 years (hazard ratio, 0.644; 95% confidence interval, 0.536–0.773; P<0.001). In the unfavorable cohort, race was not a significant prognostic factor for OS on unmatched analysis; 10-year survival 73.6% and 71.3% (hazard ratio, 0.941; 95% confidence interval, 0.848–1.044; P=0.249), and significant interaction existed with age. Results were unchanged in propensity score matched cohorts. Conclusion: The prognostic value of race-related biological differences of prostate cancer may hold less value in higher risk disease than is commonly believed.\",\"PeriodicalId\":42930,\"journal\":{\"name\":\"International Journal of Surgery-Oncology\",\"volume\":\"37 1\",\"pages\":\"e86 - e86\"},\"PeriodicalIF\":0.3000,\"publicationDate\":\"2020-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Surgery-Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/IJ9.0000000000000086\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Surgery-Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/IJ9.0000000000000086","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 1

摘要

补充数字内容可在文本中找到。引言:人们普遍认为种族是前列腺癌的重要预后因素。我们试图分析种族是否会影响接受标准护理治疗的男性的总生存率。材料和方法:所有数据来自NCDB(国家癌症数据库),最初包含2004年至2013年诊断的1,294,126例前列腺癌。如果患者有转移性或淋巴结性疾病、接受过化疗或患有非侵袭性疾病,则排除在外。患者按照NCCN(国家综合癌症网络)标准分为两组:有利风险和不利风险。所有患者都接受了风险适当的放射治疗或手术,并随后进行了分析。在每个风险队列中,黑人和白人男性也使用倾向评分进行1:1匹配,并对这些匹配的队列进行多变量分析。结果:最终队列77,448例患者。中位随访58.7个月(范围48-143.5)。在有利风险队列中,白人男性的10年OS优于黑人男性,分别为77.63%和80.57%(风险比,0.644;95%置信区间为0.536-0.773;P < 0.001)。非匹配分析显示,在不利队列中,种族不是OS的重要预后因素;10年生存率分别为73.6%和71.3%(风险比0.941;95%置信区间为0.848-1.044;P=0.249),且与年龄存在显著交互作用。结果在倾向评分匹配的队列中没有变化。结论:前列腺癌的种族相关生物学差异对高危疾病的预后价值可能低于通常认为的价值。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Race is not prognostic in unfavorable prostate cancer: an NCDB analysis
Supplemental Digital Content is available in the text. Introduction: It is commonly held that race serves as a significant prognosticator in prostate cancer. We sought to analyze whether race impacted overall survival (OS) of men receiving standard of care treatment. Materials and Methods: All data was obtained from the NCDB (National Cancer Database) and initially contained 1,294,126 cases of prostate cancer diagnosed between 2004 and 2013. Patients were excluded if they had metastatic or nodal disease, received chemotherapy, or had noninvasive disease. Patients were grouped into 2 cohorts as per NCCN (National Comprehensive Cancer Network) criteria: favorable risk and unfavorable risk. All patients received risk-appropriate radiation therapy or surgery, and were subsequently analyzed. Black and white men were also matched 1:1 within each risk cohort using propensity scores, and multivariate analysis was conducted on these matched cohorts. Results: The final cohort 77,448 patients. Median follow-up 58.7 months (range, 48–143.5). In the favorable risk cohort, white men had superior OS compared with black men, 77.63% versus 80.57% at 10 years (hazard ratio, 0.644; 95% confidence interval, 0.536–0.773; P<0.001). In the unfavorable cohort, race was not a significant prognostic factor for OS on unmatched analysis; 10-year survival 73.6% and 71.3% (hazard ratio, 0.941; 95% confidence interval, 0.848–1.044; P=0.249), and significant interaction existed with age. Results were unchanged in propensity score matched cohorts. Conclusion: The prognostic value of race-related biological differences of prostate cancer may hold less value in higher risk disease than is commonly believed.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
8
期刊最新文献
Retifanlimab: a breakthrough for the management of Merkel cell carcinoma Outcomes of the distal rectal cancer treatment depending on the type of sphincter-sparing surgery Mucinous adenocarcinoma of the urachus: a practical overview of a broad differential diagnosis: case report Spatial and temporal epidemiological analysis on the mortality rate of female breast cancer in Suzhou, China: 2006–2020 Role of Denosumab in the Management of Giant Cell Tumor, a Cross Sectional Study
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1